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Abbreviations 
AD = Atheroembolic disease 
USZ = University Hospital Zürich 
SD = standard deviation 
CI = confidence intervals 
OR = odds ratio
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Abstract 
Diagnosis of atheroembolic disease (AD) is challenging, since no specific test is available, and it of-
ten masquerades as other clinical conditions. The aim of this study was to investigate the relative 
frequency of autopsy-proven AD over time, to describe its clinical presentation and to identify risk 
factors for AD. We screened 2066 autopsy reports from the period of 1995 to 2006 for AD. For 
each AD case a control patient without AD was matched for age, sex and autopsy year. Diagnostic 
and therapeutic interventions (operations, catheter interventions and drug treatment) in the last 6 
months before death, as well as clinical and laboratory parameters during the last hospitalization 
were retrieved from electronic charts. Fifty-one AD patients were identified. Among these only 6 
(12%) had been diagnosed clinically. The organs most often affected were kidney (71%), spleen 
(37%) and lower gastrointestinal tract (22%). The relative AD frequency decreased over time from 
3.5 to 0.5/100 autopsies, whereas the frequency of clinically suspected as well as biopsy-proven AD 
remained constant. Among clinical signs, skin lesions such as livedo reticularis and blue toe (33% 
vs. 14%, p=0.04) were significantly increased in AD patients compared with the matched controls. 
Furthermore a trend for higher incidence of eosinophilia and proteinuria in AD patients was ob-
served. Vascular interventions within 6 months before death were highly associated with AD (55% 
vs. 29%, p=0.01), and in a multivariable analysis this remained the only significant risk factor for 
AD.  Thus, the diagnosis of AD is frequently missed. Vascular interventions represent the most im-
portant risk factor for AD and should be performed restrictively in high-risk patients. 
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Introduction 
Atheroembolic disease (AD), also referred to as cholesterol crystal embolization, cholesterol athe-
roembolism, or cholesterol atheromatous embolism, was first described by Flory (4) in 1944. He re-
viewed 267 autopsies and found 9 cases of AD. He described “cholesterol-crystal spaces”, where 
during tissue preparation the crystals had been dissolved in the arterial lumen and an empty crystal-
shaped space remained. Kassirer described in 1969 two types of histological lesions found in AD: at 
an early stage “crystals surrounded by eosinophilic material” were found, whereas older lesions 
showed a thickened intima, macrophages and multinucleated foreign-body giant cells. He also de-
scribed that fibrosis in the intima eventually obstructed the lumen completely. Only small vessels, 
mostly 150-200 µm in diameter were found to be affected (11). 
The pathogenesis of AD has since been further analyzed: cholesterol crystals originate from the aor-
ta in most cases (12), but can also be released from other major arteries, as long as severe atheros-
clerosis is present. To release the crystals into the bloodstream, the atheromatous plaque must be 
eroded, thus the soft core is exposed. The contents then are flushed into distal arterial beds and trig-
ger an inflammatory reaction, which eventually occludes the artery. Eliot et al. (2) distinguished be-
tween an atheroembolus, that consists of a dislodged atheromatous plaque, big enough to clog a ma-
jor artery, and a cholesterol embolus, which basically represents cholesterol crystals that occlude 
smaller arteries.  
Cholesterol crystals can be released suddenly upon spontaneous rupture of an atheromatous plaque, 
but lately iatrogenic forms of the disorder have become the center of attention. Triggers are either 
mechanical trauma - usually surgery on arteries (27), catheter interventions such as angiography or 
angioplasty (22) or drug interventions in the coagulation system such as therapeutic anticoagulation 
(18) or thrombolysis (5, 8, 21).  
The precise incidence of AD is not clear and varies in a large range depending on the risk profile of 
the patient group investigated. In a non-selected Dutch population, with an autopsy rate of 7%, 
0.31% of autopsied patients were identified to have suffered from AD (20). In contrast, in high risk 
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patient groups the incidence can raise considerably. Thurlbeck and Castleman (27) found an asto-
nishing 77% incidence in an autopsy population that had undergone aortic aneurysm repair. Mayo 
and Swartz (16), however, reported a 4% incidence among their inpatients in a renal care unit. 
Clinical diagnosis of AD remains challenging, since a multitude of different symptoms have 
been observed and only a few and unspecific laboratory findings can help to make the diagnosis. 
Therefore this study aimed to investigate the relative frequency of autopsy-proven AD over a 12-
year period, to identify risk and precipitating factors and to facilitate diagnosis of AD through iden-
tification of clinical and laboratory features of the disease.  
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Patients and Methods 
Data Collection 
We reviewed 2066 autopsy reports from autopsies performed between January 1995 through De-
cember 2006 as a retrospective single center case case-control study on patients of the Department 
of Internal Medicine at the University Hospital in Zürich, Switzerland (USZ). The search was per-
formed manually as well as through an electronic database search. A central database for patient 
charts exists in this hospital since 1995 and includes not only medical reports, but also laboratory 
values, imaging studies, ECGs and other specialized examinations. To enter the case group [group 
1], patients had to meet the following criteria: 1) Cholesterol emboli were found in at least one vital 
organ; thereby clinical and subclinical cases were not differentiated; cholesterol emboli were de-
fined as “cholesterol-crystal spaces”, where during tissue preparation the crystals had been dis-
solved in the arterial lumen and an empty crystal-shaped space remained. 2) Treatment before death 
was received at the Department of Internal Medicine at USZ, therefore all clinical and laboratory 
data were available there in digital or in printed form; 3) Autopsy was performed in the Department 
of Pathology at USZ.  
Criteria to enter the control group [group 2] were the following: 1) No cholesterol emboli had been 
found at autopsy. Criteria 2) and 3) from above were also applied for group 2. Furthermore, control 
patients were matched to case patients for sex, age and autopsy year in a 1:1 ratio. Two patients 
with AD were not matched to a control patient, because they arrived in cardiac arrest to the emer-
gency room, so that very few clinical data and no laboratory features were available for analysis.  
Pathologists performed all autopsies according to a standardized procedure, and all organs were sys-
tematically examined and analyzed by histology.  
For all case and control patients we systematically recorded data about demography, comorbidities, 
clinical manifestations of AD and precipitating factors during the last six months before death (23, 
25). These data were retrieved from an electronic chart database and manually checked where ne-
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cessary. Data on the highest recorded laboratory values were collected for the period of the last 
hospital stay before death. The cause of death was determined by the clinical and pathology reports. 
Presence of risk factors for atherosclerosis such as hypertension, hypertriglyceridemia or hypercho-
lesterolemia and diabetes were assumed when either a respective medication was prescribed or the 
diagnosis appeared in the medical history. In addition we checked laboratory records for informa-
tion on blood lipids. Hypercholesterolemia was defined by total cholesterol levels >190 mg/dL, and 
hypertriglyceridemia by total triglyceride levels >150 mg/dL (6). Tobacco abuse was recorded, 
without making a difference between current, recent or earlier tobacco use, when a history of smok-
ing of a minimum of 5 pack years was known. Acute renal failure was registered when the serum 
creatinine level doubled from baseline, according to an adapted classification of the Acute Kidney 
Injury Network (17). Chronic kidney failure was defined as either kidney damage or decreased kid-
ney function for at least 3 months (14).   
We also collected data for calculation of relative AD frequency per year in autopsies, biopsies and 
clinical cases observed in the Department of Internal Medicine at USZ. Information on total number 
of autopsies and biopsies with and without AD was retrieved from the electronic database of the 
Department of Pathology, whereas the total number of clinically suspected cases and the total num-
ber of inpatient discharges at the Department of Internal Medicine were retrieved from an electronic 
chart system by full text searches of discharge reports. 
The ethical committee for clinical studies of the Canton of Zürich approved of this study. 
 
Statistical analysis 
Descriptive Statistics were computed. Results are presented as means ± standard deviation (SD) and 
relative frequency. To skewed continuous variables such as blood serum creatinine, blood urea ni-
trogen, C-reactive protein, lactate dehydrogenase and pancreatic amylase, logarithmic transforma-
tion was applied. First, univariable and multivariable logistic regression for case/control was com-
puted. Next, univariable and multivariable conditional logistic regression analysis was performed in 
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order to control for matching in the data. A p-value of ≤0.05 was considered statistically significant. 
For comparison of relative frequencies, the Wilson method was used for the computation of 95% 
confidence intervals (CI) for the difference of true proportions. All data were analyzed with SPSS 
version 16.0 for Macintosh. Conditional logistic regression was performed with STATA Version 10 
for Macintosh. Graphs were generated in Power Point and Excel. 
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Results 
Among 2066 autopsies performed between 1995 and 2006, we found 51 patients with autopsy-
proven AD, resulting in a relative frequency of 2.5% in this particular population. Interestingly, of 
those 51 patients only 6 (12%) had been diagnosed before death.  
 
Autopsy findings in AD cases 
We first analyzed the number of affected organs in each patient (Fig. 1A). Among the 51 patients 
with AD, 22% (11/51) showed involvement of more than two organs, with up to 5 organs in 2% 
(1/51). If we further assume that clinically typical skin manifestations were indeed symptoms of AD 
(even without histological confirmation), the percentage of patients with more than one organ af-
fected rose to 61%. Thus, AD was a multisystem disorder in the majority of cases. 
When we analyzed the type of organs involved (Fig. 1B), the kidneys were most often affected, 
namely in 36/51 patients (71%), confirming earlier findings (13). The kidney was followed by 
spleen, lower gastrointestinal tract and pancreas. The group named “Others” in Fig. 1B includes 
various organs which were rarely affected by AD. Among those 6 patients, we found cholesterol 
emboli in the brain (2 patients), the adrenal glands (2 patients), thyroid gland (1 patient), and penis 
(1 patient). The last patient presented with balanitis. As this was clinically a persisting problem, at 
autopsy a sample of the penis was taken, revealing an atheroembolus.  
 
Baseline characteristics and risk factors of AD patients and controls 
In our series of AD patients, 75% were male, all of them but one were aged above 53 (mean age 
was 71 ± 11 years). One patient, who was younger than 30, had suffered from congenital heart dis-
ease. All patients were Caucasian, with the exception of one Asian female. The mean body mass in-
dex was 25.5 ± 4 kg/m2.  
For further analysis of risk factors, 49 AD patients were matched to a control group for age, sex and 
autopsy year (Table 1). Two AD patients were not matched, since they arrived dead in the hospital. 
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In both groups 98% had atherosclerosis documented by autopsy. The autopsy of the 27-year-old pa-
tient did not reveal any generalized atherosclerosis of major arteries, but one area on the aortic root, 
where atherosclerotic changes were found. We must assume this was the source of the emboli. 
Group 1 included 51% (25/49) diabetics, whereas in the control group, only 33% (16/49) had di-
abetes. This resulted in an insignificant p-value of 0.07. 
Angiography with or without angioplasty turned out to be a highly significant risk factor for AD in 
univariable analysis (Odds’ ratio [OR]=3.5, 95%CI(OR)=1.30-9.36, p=0.01), and even in condi-
tional multivariable logistic regression when controlling for matching it remained significantly as-
sociated with AD (OR=3.2, 95%CI(OR)=1.02-9.98, p=0.05). In addition, extensive surgery (joint 
replacement or opening of a body cavity) also represented a major risk factor for AD in univariable 
analysis as well as in conditional univariable logistic regression (OR=3, 95%CI(OR)=1.19-7.56, 
p=0.02), revealing no matching influence. 
In 22% (11/49) of patients neither angiography, angioplasty, surgery on arteries, nor therapeutic an-
ticoagulation had taken place in the last six months before death. In these patients AD probably oc-
curred spontaneously. However, we can not exclude that either one of these interventions had taken 
place in the time beyond 6 months before death, i.e. before the recording of our data. 
 
Presentation of AD I: clinical signs and symptoms (Table 2)   
In our series of AD patients, involvement of the skin occurred in 33% (16/49) of cases. At examina-
tion either livedo reticularis or “blue toe” was found. Skin manifestations were significantly asso-
ciated with AD in univariable analysis (OR=2.91, 95%CI(OR)=1.07-7.90, p=0.04). Results of the 
univariable conditional logistic regression were no longer significant (p=0.07). 
Acute onset of renal failure was documented in 45% (22/49) of AD patients, but this number was 
even slightly higher in the control group, in which 55% (27/49) were affected. In contrast, pre-
existing chronic renal failure was slightly more common among AD patients (61% [30/49] vs. 47% 
[23/49]), although this difference was not statistically significant (p=0.16). 
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Cholesterol emboli in retinal arteries, the so-called Hollenhorst plaques, were found in one patient. 
Unfortunately, only 6% (3/49) of AD patients underwent examination of the eye fundi. Taking all 
the charts into consideration, eye examination was reported on 5% (5/98) of the patients only.  
  
Presentation of AD II: Laboratory findings (Table 2) 
Only 59% (58/98) of all reviewed charts contained urinalysis results. Hematuria was classified posi-
tive with ≥2+ by dipstick. In univariable analysis hematuria was significantly associated with the 
control group (OR=0.26, 95%CI(OR)=0.08-0.88, p=0.03). However, in conditional logistic regres-
sion when controlling for matching, it was no longer significant (p=0.14). Proteinuria was graded 
positive if the dipstick showed ≥1+. It showed a tendency for association with AD, although it did 
not reach significance (p=0.07) in univariable analysis. Overall kidney function did not differ be-
tween the two groups: the mean value of the peak serum creatinine was 3.04±2.22 mg/dl in AD pa-
tients and 2.94±1.83 mg/dl in controls. 
Eosinophilia was reported to be frequently associated with AD (1, 7, 10, 16, 23). In our patient pop-
ulation, absolute eosinophil counts were available for 64 patients. Eosinophil counts above 500/µL 
were found in 17% (7/41) of AD patients, but only 6% (2/32) of controls. This yielded an OR >3, 
which however was not significant (p=0.18). Thus, we conclude that presence of eosinophilia 
should raise a high clinical suspicion of AD, although its absence cannot exclude it. 
The optimal multivariable logistic regression was found to have 2 predictors: C-reactive protein 
(OR=0.995, 95%CI(OR)=0.991-0.999, p=0.019), which was available for all cases and controls, 
and angiography (OR=4.1, 95%CI(OR)=1.46- 11.75, p=0.007). Conditional logistic regression also 
revealed that C-reactive protein (OR=0.996, 95%CI(OR)=0.99-1, p=0.09) and angiography 
(OR=3.2, 95%CI(OR)=1.02-9.98, p=0.045) were significantly associated with AD, therefore ex-
cluding any matching influence. Based on the OR’s among these two parameters only angiography 
was considered clinically significant. 
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Causes of death 
One patient clearly died from extensive atheroembolic disease: 5 of his organs were affected in ad-
dition to typical skin lesions, and the disease led to acute renal failure. Overall, 69% (35/51) of the 
patients in group 1 died from cardiovascular causes, and AD may have played a role to a variable 
extent. The main other causes of death were sepsis in 16% (8/51) and neoplasia in 12% (6/51). In 
comparison, the causes of death in group 2 were cardiovascular in 49% (24/49), sepsis in 29% 
(14/49) and neoplasia in 22% (11/49). Thus, a tendency for a higher incidence of cardiovascular 
death was found in the AD group (OR = 2.28, p = 0.05)  
 
Relative frequency of AD over time in autopsy, biopsy and clinical diagnosis  
We first analyzed the relative frequency of AD per 100 autopsies in each year of the 12-year period 
from 1995 to 2006 and surprisingly found a decrease from 3.5 to 0.5 /100 autopsies (Fig. 2A). This 
however, was not statistically significant: the 95%CI for the difference of true proportions between 
years 1995 and 2006 is (-0.018, 0.06) revealed no difference in the relative frequencies between 
both years. During the same time, the overall number of autopsies had also declined. However, the 
median age of autopsied patients for the years 1995, 2000, and 2006 remained stable at 64.5 years, 
therefore not indicating any severe selection bias over time. Furthermore, differences in autopsy 
techniques could be excluded, as those standards have not changed over the years. 
To evaluate whether this decline of AD in autopsy represents a real decline of the occurrence of 
disease in our observation period, we analyzed the relative frequency of biopsy-proven AD (Fig. 
2B) and of clinical AD diagnoses (Fig. 2C) during the same time period in the Department of Inter-
nal Medicine at USZ. The former was normalized to the total number of biopsies, the latter to the 
total number of discharges of the respective year. For both analyses the relative frequency was sta-
ble over time. 
One possible explanation for the difference between autoptic and clinical diagnoses of AD could be 
a better prognosis of AD due to an increased use of potentially protective medications such as sta-
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tins and aspirin. Therefore we retrieved available data of the use of statins and aspirin from the 
records of the hospital pharmacy and found that indeed between 2000 and 2008 the delivery of sta-
tins to the wards at USZ has increased from 18’800 to 41’000 tablets a year, whereas during that 
same period of time delivery of aspirin remained stable. 
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Discussion 
AD occurred at a frequency of 2.5% in a large autopsy series from patients deceased in the Depart-
ment of Medicine of a major Swiss university hospital between 1995 and 2006. Due to a possible 
selection bias in the patient population of a tertiary care hospital, which admits a higher percentage 
of severely ill patients compared to other hospitals, this frequency may not be extrapolated directly 
to the general population. Of interest, AD was frequently missed clinically, since only 12% of the 
AD cases detected by autopsy were diagnosed ante mortem. The relative frequency of autopsy-
proven AD had a tendency to decrease over time, whereas diagnoses of AD on biopsies and clinical 
diagnoses remained constant.  
In table 3 our study cohort is compared to the cohorts of 4 previous studies. The table reveals a high 
variability in frequency of risk factors and symptoms of AD, which may partially reflect the use of 
different selection criteria, but also the high variability of clinical presentation of this disease.  
 
Angiography and major arterial surgery are reported as two major risk factors for AD, especially in 
elderly patients with suspected atherosclerosis (22, 27). Our study confirmed this for angiography 
with a high significance even in multivariable analysis. During either of these two interventions, 
mechanical manipulation of blood vessels causes atheroembolic plaques to disrupt, and subsequent-
ly this debris might clog smaller peripheral arteries. In case of extensive extra-arterial surgery, such 
as a joint replacement or the opening of a body cavity, stress or pain-related hypertension cause 
shear forces which can promote atheromatous plaque rupture. In addition anticoagulants, which are 
given to prevent postoperative thrombosis, are also known to favor atheroembolic disease (18). 
However, the prophylactic dosage given after surgery, was found to be statistically insignificant in 
our study population.  
 
Not every histological finding of cholesterol crystals in tissues leads to a clinically relevant disease 
manifestation. Therefore retrospective data derived from autopsy or biopsy studies may exaggerate 
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AD frequency (24). But still AD remains highly under-diagnosed and remains a marker of high 
atherosclerotic burden and therefore cardiovascular risk. In our autopsy collective, 88% were clini-
cally missed, although almost all presented with typical risk factors and 33% had either livedo reti-
cularis or blue toe as common skin symptoms. In our study cutaneous manifestations were signifi-
cantly associated with AD. With 33% they are similar to earlier studies (3). In contrast, recently 
published studies report skin manifestations in 88-96% (1, 9, 24), most likely because lesions were 
systematically looked for and even subtle signs were recorded. Skin symptoms can first appear 
within a month after the intervention (15, 25), and might be better visible, if the patient is in an 
upright position (9). Biopsy confirms the diagnosis. If biopsy specimens are not taken too superfi-
cially (18), sensitivity reaches 86% (9). 
Besides a variety of symptoms, which often are not conclusive, few laboratory features help to 
make the diagnosis of AD. Eosinophilia has been pointed out to be present for 2-3 days in early 
stages of the disease, and therefore can be easily missed (10). In contrast, Thériault et al. (26) stated 
that eosinophilia was present more than 1 month after AD diagnosis. This leads to the assumption 
that the presence of eosinophilia is alternating over a long period of time. The fact that this finding 
has been reported in several other studies with varying percentages between 44-100% (1, 7, 10, 16, 
23) reinforces this theory. In our series, we must assume that eosinophilia was missed in several 
other cases, because our study did not include long term surveillance, nor were eosinophil counts 
collected regularly, both measures necessary to comply with the episodical appearance of eosino-
philia.  
The kidney is often targeted in AD. Scolari et al. (24) suggested that the proximity to the abdominal 
aorta, and the large renal blood supply are the reason for the frequent involvement. In our series, 
71% of the examined kidney samples, showed the typical crystal shaped clefts. This could have led 
to the higher percentage of chronic renal disease and proteinuria in group 1. Indeed, urinalysis 
might give helpful clues towards diagnosis of AD. Search for proteinuria should be performed, as 
this has regularly been observed in AD patients (7, 25). Greenberg et al. stated in their study, that 
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two distinct populations among AD patients exist and that in those patients with heavy proteinuria 
(38% in their series) focal segmental glomerulosclerosis with capillary loop collapse was found in 
78% (7).  
 
 
 
Although incidence of AD is reported to be less than 5% (13, 16, 20), mortality and especially mor-
bidity, as well as the economic impact of the disease are considerable (9, 13). Thus timely diagnosis 
is required and can be achieved with a high level of clinical suspicion. White men, older than 50 
years, who present with classical symptoms and risk factors of advanced atherosclerosis, are prone 
to suffer from this medical condition (23). When undergoing any kind of intervention on arteries, 
monitoring for AD should take place. Common findings of AD are blue toe, livedo reticularis, or 
renal failure. But AD can also cause pancreatitis, muscle pain, gastrointestinal bleeding, hyperten-
sion, peptic ulcer, inflammatory bowel disease (19), as well as prostatitis, and hemorrhagic cystitis 
(20).  Therefore AD often masquerades as presumed other clinical conditions. Even the balanitis in 
one of our patients might have occurred as a consequence of AD. Molinari et al. reported to have 
“observed singular reports of cholesterol crystal embolization in connection with skin hyperplasia 
and atrophy, […], lichen ruber planus, preputial ulcer, and basalioma” (20).  
If a patient is diagnosed with this disease, early and aggressive therapy should be initiated, since the 
prognosis for renal and patient survival is dismal, when multivisceral involvement occurs (1). One 
therapy approach by Belenfant et al. (1) aimed to prevent the three major causes of death in AD ac-
cording to earlier published studies: “recurrence of cholesterol crystal embolization, cardiac failure 
and cachexia”. They used a combination of blood pressure lowering agents, hemodialysis, nutri-
tional support, corticosteroids, discontinuation of anticoagulation treatment, and no further use of 
any intra-arterial interventions. Corticosteroids were administered in low doses and improvements 
in clinical status, as well as pain relief, were reported (1). However, use of corticosteroids still re-
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mains controversial. Scolari et al. when publishing their multicentre study on 354 patients in 2007, 
stated, that no difference in outcome was noted, when giving steroids (23). A surgical approach for 
the management of affected patients has also been discussed in the past. After surgical removal of 
the sources of atheroemboli, a lower morbidity and less recurrence of AD as well as better outcome 
considering limb loss was observed, but this finding did not apply to the suprarenal aorta, that is be-
lieved to be the main source of thrombi (12). However, with still limited therapy options, no causal 
treatment available, and high morbidity, prevention of atheroembolic disease must be the first prior-
ity. 
 
Taken together, our matched-pair autopsy study demonstrated that AD is still frequently missed in 
over 80% of the cases. Typical skin lesions and a history of atherosclerosis or arterial interventions 
should raise a high level of clinical suspicion and lead to simple clinical exams (such as looking for 
Hollenhorst plaques in the eye fundi) and screening for organ dysfunction (such as renal failure).  
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Figure Legends 
 
Figure 1. Organ distribution of atheroemboli in autopsies 
(A) Numbers of organs affected by atheroembolic disease. (B) Type of organs affected by athe-
roembolic disease. Multiple listings are possible. We divided the gastrointestinal tract (GI tract) into 
an upper tract including esophagus, stomach, and duodenum, and a lower tract including jejunum, 
ileum and colon.  
 
Figure 2. Relative frequency of AD over time 
(A) Atheroembolic disease (AD) in autopsy, normalized to the total number of autopsies/year. (B) 
In biopsy, normalized to the total number of biopsies/year. (C) In clinical diagnosis, normalized to 
the total number of hospital discharges/year. All numbers refer to patients hospitalized in the De-
partment of Medicine at University Hospital Zurich (Switzerland).   
 
 
 


Table 1.  Risk factors for atherosclerosis and atheroembolism in cases versus controls 
 Descriptive statistics  (N/N; %)  
Univariable  
logistic regression  
Univariable conditional  
logistic regression 
Medical history Cases Controls   OR P-value  OR 95%CI (OR) P-value 
Diabetes mellitus (25/49) 51% (16/49) 33%  2.148 0.067     
Hypertension (28/49) 57% (25/49) 51%  1.280 0.543     
Tobacco use (≥ 5 years) (28/40) 70% (20/31) 65%  1.238 0.677     
Hypertriglyceridemia or hypercholesterolemia (21/25) 84% (18/24) 75%  1.75 0.438     
Symptomatic arterial disease (47/49) 96% (45/49) 92%  2.089 0.408     
Therapeutic interventions 
Therapeutic anticoagulation (18/47) 38% (10/48) 21%  2.359 0.065  2.8 1-7.77 0.048 
Platelet aggregation inhibitors (31/49) 63% (22/49) 45%  2.114 0.07     
Statin use (7/49) 14% (8/49) 16%  0.854 0.779     
Angiography (18/49) 37% (7/49) 14%  3.5 0.01  3.75 1.2-11.3 0.019 
Surgery on arteries (9/49) 18% (3/49) 6%  3.45 0.077     
Extensive surgery (all but surgery on arteries) † (34/49) 69% (22/49) 45%  2.782 0.015  3.00 1.19-7.56 0.02 
Angiography, angioplasty or surgery on arteries (27/49) 55% (14/49) 29%  3.068 0.009  3.17 1.26-7.93 0.014 
 
OR = odds ratio 
CI = confidence intervals 
† Extensive surgery was defined as opening of a body cavity or prosthesis implantation; in this group we also included two patients who received 
an intraaortic balloon pump. 
Table 2.   Symptoms and signs of atheroembolism in cases versus controls 
 Descriptive statistics (N/N; %) or (Median±SD) 
 Univariable  
logistic regression 
 Univariable conditional 
logistic regression 
Symptoms Cases Controls  OR P-value  OR 95%CI (OR) P-value 
Abdominal Symptoms*  (26/49) 53% (24/49) 49%  1.178 0.686     
Muscle pain (6/49) 12% (3/49) 6%  2.140 0.303     
Gastrointestinal bleeding (10/49) 20% (14/49) 29%  0.641 0.349     
Skin manifestation (Livedo reticularis, blue toe)  (16/49) 33% (7/49) 14%  2.909 0.036    0.068 
Signs          
Proteinuria ◊ (19/22) 86% (23/36) 64%  3.580 0.073     
Hematuria ∆ (5/21) 24% (19/35) 54%  0.263 0.030     
Pancreatic amylase (U/L) ∞  42±223.09 29±60.11  1.005 0.154     
Blood serum creatinine (mg/dl) ∞  2.17±2.22 2.44±1.83  1.00 0.793     
Blood Urea Nitrogen (mg/dl) ∞ 39.21±56.02 56.02±30.81  0.998 0.898     
Lactate dehydrogenase (U/L) ∞ 851.5±6942 777±4145  1.00 0.993     
C-reactive protein (mg/dl) ∞ 142±102.94 182±109.93  0.996 0.034  0.995 0.99-0.9995 0.031 
Eosinophilia (> 500/µL) (7/41) 17% (2/32) 6%  3.09 0.179     
 
SD = standard deviation 
OR = odds ratio 
CI = confidence intervals 
* Abdominal symptoms defined as: emesis, diarrhea or abdominal pain 
◊ Proteinuria defined as: dipstick indicating ≥1+ 
∆ Hematuria defined as: dipstick indicating ≥2+ 
∞ Laboratory data recorded: highest values during last hospitalization before death 
